Results 41 to 50 of about 74,225 (263)

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

The discovery of a novel series of potential ERRα inverse agonists based on p-nitrobenzenesulfonamide template for triple-negative breast cancer in vivo

Journal of Enzyme Inhibition and Medicinal Chemistry, 2022
Oestrogen related receptor α participated in the regulation of oxidative metabolism and mitochondrial biogenesis, and was overexpressed in many cancers including triple-negative breast cancer.
Zhipei Gao, Tianxiao Wang, Rui Li, Yongli Du, Han Lv, Liudi Zhang, Haifei Chen, Xiaojin Shi, Qunyi Li, Jingkang Shen   +9 more
doaj   +1 more source

Neural Functions Play Different Roles in Triple Negative Breast Cancer (TNBC) and non-TNBC [PDF]

, 2019
Triple negative breast cancer (TNBC) represents the most malignant subtype of breast cancer, and yet our understanding about its unique biology remains elusive. We have conducted a comparative computational analysis of transcriptomic data of TNBC and non-
Gao, Xin, Huang, Zhenyu, Xu, Ying, Zhou, Yi, Tan, Renbo, Tao, Mingxin, Li, Haoyang   +6 more
core   +1 more source

Defining triple‐negative breast cancer with neuroendocrine differentiation (TNBC‐NED)

, 2023
Primary breast neuroendocrine (NE) neoplasms are uncommon, and definitions harbor controversy. We retrospectively collected 73 triple‐negative breast cancers (TNBC) and evaluated NE biomarker expression along with p53 aberrant staining (which correlates ...
Sean M Hacking, Evgeny Yakirevich, Yihong Wang   +2 more
core   +1 more source

Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer

Molecular Oncology, EarlyView.
Extracellular vesicle (EV) lipidomic profiling of plasma and ascites from patients with high‐grade serous ovarian cancer and of ovarian cancer cell lines reveals enrichment of triglycerides (TGs), diacylglycerols (DGs), phosphatidylcholine (PCs), sphingomyelins (SMs), reflecting tumor metabolic reprogramming.
Shikha Rani, Dominic Guanzon, Andrew Lai, Katherin Scholz‐Romero, Sarah Reed, Edita Ritmejeryte, Rohan Lourie, Naven Chetty, Kaltin Ferguson, Carlos Salomon   +9 more
wiley   +1 more source

Mutant p53–Nrf2 axis regulates the proteasome machinery in cancer

Molecular & Cellular Oncology, 2017
The proteasome machinery is a common target of gain-of-function p53 missense mutants. Upregulation of the proteasome fosters chemoresistance to proteasome inhibitors.
Kamil Lisek, Dawid Walerych, Giannino Del Sal   +2 more
doaj   +1 more source

Machine Learning Approaches to Predict Neoadjuvant Chemotherapy Response and Metastasis in Women with Triple-Negative Breast Cancer Based on Tumor Microenvironments [PDF]

Background: Triple Negative Breast Cancer (TNBC) is an aggressive breast cancer subtype that lacks expression of estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) receptors. Neoadjuvant chemotherapy (NAC), or chemotherapy given
Fisher, Timothy
core   +1 more source

Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)

, 2023
Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and is characterized by an aggressive nature and a high rate of recurrence despite neoadjuvant and adjuvant chemotherapy.
Jieun Lee, Lee, Jieun
core   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer

OncoImmunology, 2020
Triple-negative breast cancer (TNBC) is characterized by broad genomic and transcriptional heterogeneity and results in a worse prognosis than other breast cancer types.
Hao Chen, Wei Chong, Xiaorong Yang, Yuan Zhang, Shaowei Sang, Xiangchun Li, Ming Lu   +6 more
doaj   +1 more source